Ozempic fattens Commonwealth coffers – slightly

Payroll tax
Ozempic manufacturer, Novo Nordisk’s tax bill more than doubled in the 2021/22 financial year, data from the Australian Taxation Office (ATO) reveals  Surging demand for Novo Nordisk’s diabetes medication, Ozempic (semaglutide), for off-label use as a weight-loss wonder drug, appears to be behind a $100 million jump in the firm’s total income in Australia.  

This content is restricted to registered users only. If you have already registered on the AJP website please login below, Or you can Register for free.

Forgot Password?Why do I need to login & stay in?

Previous BioCeuticals issues product recall
Next NAPSA confirms new research chair